Apple launches app to study how Americans use AI chatbots for health questions
Apple has started a large study of how people use conversational AI for medical questions, with answers grounded in clinical sources. The study runs with OpenEvidence and is open to iPhone users in the U.S.

William Hook · Unsplash License
- 0views
- 0likes and saves
- 0skips
In brief
- Apple has launched an iOS app for a large study of how people use AI chatbots for health questions.
- The study is run with OpenEvidence and targets up to 200,000 adult U.S. iPhone users over more than 12 months.
- Answers are based on clinical research and are rated by participants, who can also share HealthKit data.
Study design and eligibility
Apple has released a new iOS app for a study of how people use AI tools to answer health questions. The company is running the work with OpenEvidence, a healthcare-focused AI company whose platform is used by clinicians. (Apple launches new app to study how people use AI for health – TechCrunch) (Apple’s new study looks to improve the effectiveness of AI health tools – The Verge)
The study is open to adults in the U.S. over 21 who own an iPhone 15 or later, run iOS 26 or later, and have Apple Intelligence turned on. Apple aims to enroll up to 200,000 participants over more than 12 months.
How the app works
Users can put everyday medical questions to the app, much as they would to a general chatbot.
Participants rate each answer on accuracy, level of detail and relevance, and can leave written feedback. They are also asked to complete monthly surveys.
Data sharing
Participants may choose to share health data from Apple's HealthKit, such as resting heart rate, with the study.
Enrollment
The app is available for download now, and enrollment opened the same day Apple announced the study.
Why it matters
Large AI developers including OpenAI and Anthropic have built chatbot features aimed at health queries. Apple's study takes a different angle by testing whether answers tied to clinical sources are more useful to users than general responses.
Sources
Discussion0
- No comments from this perspective yet. Be the first.
